Benzene Ring Bonded Directly To The 4-position Of The Triazole Ring Patents (Class 548/264.6)
  • Patent number: 9340529
    Abstract: This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: May 17, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicholas David Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan Michael Ghergurovich, Terence John Kiesow, Cynthia Ann Parrish, Alexander Joseph Reif, Kenneth Wiggall
  • Publication number: 20150139905
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 21, 2015
    Inventors: Dinesh Chimmanamada, Weiwen Ying
  • Publication number: 20150111910
    Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
    Type: Application
    Filed: May 22, 2013
    Publication date: April 23, 2015
    Applicant: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Agostino Marasco, Giuseppe Alvaro, Anne Dècor, Dieter Hamprecht, Paolo Dambruoso, Simona Tommasi
  • Publication number: 20150051203
    Abstract: A compound of structural formula (I) or (II): as HSP90 inhibitors that possess significantly improved bioavailability over comparative compounds, which are suitable for the treatment of hyperproliferative diseases such as cancer, infections, immune disorders, inflammation, and CNS related disorders.
    Type: Application
    Filed: March 27, 2013
    Publication date: February 19, 2015
    Inventors: Dinesh Chimmanamada, Zachary Demko, Weiwen Ying
  • Patent number: 8927548
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: January 6, 2015
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, David James, Shijie Zhang, Junghyun Chae, Teresa Kowalczyk-Przewloka, Howard P. Ng, Hao Li, Zachary Demko, Dinesh U. Chimmanamada, Chi-wan Lee, Zhenjian Du, Kevin Foley, Minghu Song, Lijun Sun, Keizo Koya, Dan Zhou, Shuzhen Qin
  • Patent number: 8816070
    Abstract: 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: August 26, 2014
    Assignee: Merck Patent GmbH
    Inventors: Hans Michael Eggenweiler, Michael Wolf, Hans Peter Buchstaller, Christian Sirrenberg
  • Patent number: 8802864
    Abstract: This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: August 12, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicholas D. Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan M. Ghergurovich, Terence John Kiesow, Cynthia A. Parrish, Alexander Joseph Reif, Kenneth Wiggall
  • Publication number: 20140079636
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to an binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 20, 2014
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Patent number: 8628869
    Abstract: According to one embodiment, a lubricant includes a perfluoropolyether having a chemical structure of: wherein Rf is at least one of: —CF2O(CF2CF2O)m(CF2O)nCF2— and —CF2CF2O(CF2CF2CF2O)kCF2CF2—, with m representing 0 or a positive integer, n representing 0 or a positive integer, and k representing 0 or a positive integer, and wherein R1 to R4 are selected from a group consisting of —H or with at least one of R1 to R4 being
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: January 14, 2014
    Assignee: HGST Netherlands B.V.
    Inventors: Mina Amo, Katsumi Mabuchi, Hiroshi Yoshida, Bruno Marchon, Qing Dai
  • Patent number: 8618285
    Abstract: Novel triazole derivatives of the formula (I), in which R1-R6, and Y have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: December 31, 2013
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Michael Wolf
  • Publication number: 20130116431
    Abstract: Disclosed is a triazole derivative(s) represented by the general formula (1) below or a pharmacologically acceptable salt(s) thereof. Also disclosed are a prodrug(s) of such a triazole derivative(s) and an HSP90 inhibitor(s) containing any one of them as an active constituent. (1) (In the formula, X represents a halogen atom, an optionally substituted alkyl group, an optionally substituted alkynyl group or the like; Y represents a mercapto group, a hydroxyl group, an optionally substituted sulfonyl group, an optionally substituted amino group or the like; and R represents an optionally substituted aryl or alkyl group or the like.
    Type: Application
    Filed: November 5, 2012
    Publication date: May 9, 2013
    Applicant: Nippon Kayaku Kabushiki Kaisha
    Inventor: Nippon Kayaku Kabushiki Kaisha
  • Publication number: 20130085147
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: November 7, 2012
    Publication date: April 4, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventor: Bristol-Myers Squibb Company
  • Publication number: 20120330009
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Application
    Filed: July 16, 2012
    Publication date: December 27, 2012
    Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
  • Publication number: 20120316151
    Abstract: This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Application
    Filed: February 22, 2011
    Publication date: December 13, 2012
    Inventors: Nicholas D. Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan M. Ghergurovich, Terence John Kiesow, Cynthia A. Parrish, Alexander Joseph Reif, Kenneth Wiggall
  • Patent number: 8318790
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: November 27, 2012
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, David James, Shijie Zhang, Junghyun Chae, Teresa Przewloka, Howard P. Ng, Hao Li, Zachary Demko, Dinesh U. Chimmanamada, Chi-wan Lee, Zhenjian Du, Kevin Foley, Minghu Song, Lijun Sun, Keizo Koya, Dan Zhou, Shuzhen Qin
  • Publication number: 20120122869
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 17, 2012
    Inventors: Weiwen Ying, David James, Shijie Zhang, Junghyun Chae, Teresa Przewloka, Howard P. Ng, Hao Li, Zachary Demko, Dinesh U. Chimmanamada, Chi-wan Lee, Zhenjian Du, Kevin Foley, Minghu Song, Lijun Sun, Keizo Koya, Dan Zhou, Shuzhen Qin
  • Patent number: 8093400
    Abstract: The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y? are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: January 10, 2012
    Assignee: Pfizer Inc.
    Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
  • Publication number: 20110294819
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: December 21, 2010
    Publication date: December 1, 2011
    Inventors: Omar D. Lopez, Denis R. St. Laurent, Jason Goodrich, Jeffrey Lee Romine, Michael Serrano-Wu, Fukang Yang, Ramesh Kakarla, Xuejie Yang, Yuping Qiu, Lawrence B. Snyder
  • Publication number: 20110245308
    Abstract: The present application relates to new, substituted benzyl-1,2,4-triazolones and phenylsulfonyl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: November 26, 2009
    Publication date: October 6, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: UIf Brüggemeier, Ingo Flamme, Chantal Fürstner, Joerg Keldenich, Peter Kolkhof, Martina Delbeck, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Truebel
  • Publication number: 20110105749
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Application
    Filed: June 14, 2010
    Publication date: May 5, 2011
    Inventors: Weiwen YING, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
  • Publication number: 20100113542
    Abstract: 5-[4-(2-Methylphenyl)-3-hydroxy-4H-1,2,4-triazol-5-yl]-2,4-dihydroxy-N-methyl-N-butylbenzamide is an HSP90 inhibitor and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: December 11, 2007
    Publication date: May 6, 2010
    Applicant: Merck Patent Gesellschaft
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Hans Peter Buchstaller, Christian Sirrenberg
  • Publication number: 20100113447
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound.
    Type: Application
    Filed: August 10, 2009
    Publication date: May 6, 2010
    Inventors: Joseph A. Burlison, Shijie Zhang, Weiwen Ying, Dinesh U. Chimmanamada, Minghu Song, Junghyun Chae, Stefan M. Schweizer
  • Patent number: 7662813
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: February 16, 2010
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Elena Kostik, Junghyun Chae, Howard P Ng, Zhenjian Du, James Barsoum, Dinesh Chimmanamada, Chi-Wan Lee, Kevin Foley
  • Publication number: 20090091234
    Abstract: A salt molten at room temperature that does not contain any organic solvent, excelling in stability; and a display device that is improved in the durability in high-temperature environment by virtue of the use thereof. There is provided a salt molten at room temperature characterized by being composed of a silver salt and any of compounds of the following general formula (I) or general formula (II).
    Type: Application
    Filed: April 6, 2006
    Publication date: April 9, 2009
    Applicant: KONICA MINOLTA HOLDINGS, INC.
    Inventor: Noriyuki Kokeguchi
  • Patent number: 7449266
    Abstract: Perfluoropolyether benzotriazole compounds and compositions containing perfluoropolyether benzotriazole compounds are provided. The perfluoropolyether benzotriazole compounds can be attached to a substrate having a metal or metal oxide-containing surface to provide at least one of the following characteristics: anti-soiling, anti-staining, ease of cleaning, repellency, hydrophobicity, or oleophobicity.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: November 11, 2008
    Assignee: 3M Innovative Properties Company
    Inventors: Richard M. Flynn, Naiyong Jing, Mark J. Pellerite
  • Publication number: 20080139560
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.
    Type: Application
    Filed: March 7, 2005
    Publication date: June 12, 2008
    Inventors: Robert Zelle, Vincent P. Galullo
  • Patent number: 7148360
    Abstract: Perfluoropolyether benzotriazole compounds and compositions containing perfluoropolyether benzotriazole compounds are provided. The perfluoropolyether benzotriazole compounds can be attached to a substrate having a metal or metal oxide-containing surface to provide at least one of the following characteristics: anti-soiling, anti-staining, ease of cleaning, repellency, hydrophobicity, or oleophobicity.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: December 12, 2006
    Assignee: 3M Innovative Properties Company
    Inventors: Richard M. Flynn, Naiyong Jing, Mark J. Pellerite
  • Patent number: 7067656
    Abstract: A sulfamoyl compound of the general formulae (1): wherein R1 and R2 are each independently C1-4 alkyl, or R1 and R2 together are C4-6 alkylene or C4-6 alkyleneoxy, Y is H, halogen, C1-8 alkyl, C1-8 alkoxy, C1-8 alkylthio, C1-8 haloalkyl, C1-8 haloalkoxy or C1-8 haloalkylthio, A is a predetermined heterocyclic group, B is a predetermined heterocyclic group which is identical with or different from A, W is a chemical bond or O, V is O or S, D, E, F and G are each independently N, CR7, CR8, CR9 or CR10, and R3, R4, R5, R6, R7, R8, R9, R10 and R11 are each independently predetermined group such as H, or an unsubstituted or substituted aliphatic, aromatic or heterocyclic group. The sulfamoyl compound is useful as an agricultural and horticultural fungicide.
    Type: Grant
    Filed: July 9, 2003
    Date of Patent: June 27, 2006
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Toshiaki Takeyama, Toshimasa Hamada, Hiroaki Takahashi, Junichi Watanabe, Kazuhiro Yamagishi, Masanori Nishioka, Hiroyuki Suzuki
  • Patent number: 7056941
    Abstract: 2-[Pyrazolyl- and triazolyl-3?-oxymethylene]phenylisoxazolones, -triazolones and -tetrazolones of formula I where: X is a group A, B or C, ?where # denotes the bond with the phenyl ring, Ra is hydrogen, halogen, alkyl or alkoxy, Rb is alkyl; Y is N or CRc, where Rc is hydrogen, halogen or alkyl; n is 0, 1, 2, 3 or 4, where the substituents R1 may be different if n is greater than 1; R1 is nitro, cyano, halogen, alkyl with or without substitution or alkoxy with or without substitution or is additionally, if n is 2, an optionally substituted 3 or 4 membered bridge which forms together with the ring to which it is attached a bicyclic partially unsaturated or aromatic radical; R2 is hydrogen, nitro, cyano, halogen, alkyl, haloalkyl, alkoxy, alkylthio or alkoxycarbonyl; R3 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted hetaryl, their preparation and their use for controlling unwanted animal pests or harmful fungi.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: June 6, 2006
    Assignee: BASF Aktiengesellschaft
    Inventors: Bernd Müller, Hubert Sauter, Herbert Bayer, Markus Gewehr, Wassilios Grammenos, Thomas Grote, Andreas Gypser, Arne Ptock, Reinhard Kirstgen, Norbert Götz, Roland Götz, Franz Röhl, Eberhard Ammermann, Volker Harries, Gisela Lorenz, Siegfried Strathmann
  • Patent number: 6964939
    Abstract: The invention relates to novel substituted thien-3-yl-sulphonylamino(thio)carbonyl-triazolin(ethi)ones of the general formula (I) in which Q1, Q2, R1, R2, R3 and R4 are each as defined in the description, and to salts of the compounds according to formula (I), to processes and to novel intermediates for their preparation and to their use as herbicides.
    Type: Grant
    Filed: July 4, 2000
    Date of Patent: November 15, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ernst Rudolf F. Gesing, Joachim Kluth, Klaus-Helmut Müller, Mark Wilhelm Drewes, Peter Dahmen, Dieter Feucht, Rolf Pontzen
  • Patent number: 6716841
    Abstract: This invention relates generally to nitrogen containing heterobicycles of formulas A and B: which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: April 6, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Irina C. Jacobson, Mimi L. Quan
  • Patent number: 6710049
    Abstract: The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared with presently available agents in this class and the processes for the preparation thereof. This invention also relates to pharmaceutical preparations containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 23, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Mohammed Salman, Rita Katoch, Ashwani Kumar Verma, Jitendra Sattigeri, Ashok Rattan
  • Patent number: 6693124
    Abstract: Bisimino-substituted phenyl compounds of the formula I where the substituents have the following meanings: X is a group A or B  where # denotes the bond with the phenyl ring and Ra is halogen, alkyl or alkoxy; Y is halogen, alkyl, haloalkyl or alkoxy; n is 0, 1 or 2, it being possible for the radicals Y to be different if n=2; R1 is alkyl; R2 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl or haloalkynyl; R3 is hydrogen, alkyl, haloalkyl or substituted or unsubstituted phenyl; R4 is ═CRbRc or ═N—ORd where Rb, Rc independently of one another are hydrogen, alkyl or substituted or unsubstituted phenyl; and Rd is one of the radicals mentioned under R2. Processes and intermediates for their preparation, and their use.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: February 17, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Wassilios Grammenos, Herbert Bayer, Thomas Grote, Hubert Sauter, Andreas Gypser, Reinhard Kirstgen, Bernd Müller, Arne Ptock, Franz Röhl, Gisela Lorenz, Eberhard Ammermann, Siegfried Strathmann, Volker Harries
  • Patent number: 6492406
    Abstract: The present invention relates to novel compounds which are protein kinase C inhibitors, methods for their preparation, intermediates therefor and pharmaceutical compositions comprising them. More particularly, the present invention relates to compounds of formula (I): wherein: one of Ar1 and Ar2 is optionally substituted bicyclic heteroaryl or optionally substituted tricyclic heteroaryl and the other is optionally substituted heteroaryl or optionally substituted aryl; X is O or S; and R is H, OH, NH2 or C1-6 alkyl (itself optionally substituted by amino or hydroxy); or a salt or solvate thereof, or a solvate of a salt thereof; and the use of such compounds in medical therapies.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: December 10, 2002
    Assignee: Astrazeneca AB
    Inventors: Kostas Karabelas, Matti Lepistö, Peter Sjö
  • Patent number: 6489487
    Abstract: Triazolone derivatives represented by the formula wherein R1 represents optionally substituted C1-10 alkyl, A1—L1—, A1—ON═CA2, etc.; R2 represents hydrogen, C1-6 alkyl, etc.; R3 represents C1-6 alkoxy, etc.; one of T, U, and V represents CR4, another represents CH or nitrogen, and the remaining one represents CR5 or nitrogen; and W represents CR6 or nitrogen.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: December 3, 2002
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Akio Manabe, Yoshiharu Kinoshita, Hiroshi Sakaguchi, Tomohiro Araki
  • Patent number: 6436981
    Abstract: Compounds of formula 1 wherein: Y signifies halogen, C1-C4-alkoxy, C1-C4-alkylthio or hydroxy; R1 signifies methyl, ethyl or cyclopropyl; R2 signifies C1-C6-alkyl or C1-C6-alkyl substituted by 1 to 5 fluorine atoms; R3 is C1-C6-alkyl, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkoxy, C2-C6-alkenyl, C2-C6-alkenyloxy, C2-C6-alkinyl, C2-C6-alkinyloxy, C1-C6-alkoxycarbonyl or CN, whereby, with the exception of CN, the above-mentioned groups may be substituted by identical or different substituents; or R3 is aryl, heteroaryl, heterocyclyl, aryloxy, heteroaryloxy or heterocyclyloxy, whereby the above-mentioned groups may be substituted by identical or different substituents, R5 signifies hydrogen or methyl; have microbicidal, insecticidal and acaricidal activity and may be used to control insects and plant-pathogenic fungi in agriculture, horticulture and in the field of hygiene.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: August 20, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventor: Hugo Ziegler
  • Patent number: 6383988
    Abstract: The invention relates to novel thienylsulphonylamino(thio)carbonyl compounds of the formula (I), in which Q represents oxygen or sulphur, R1 represents cyano, halogen or in each case optionally cyano-, halogen- or C1-C4-alkoxy-substituted alkyl, alkenyl, alkinyl, alkoxy, alkenyloxy or alkinyloxy having in each case up to 6 carbon atoms, R2 represents cyano, halogen or in each case optionally cyano-, halogen- or C1-C4-alkoxy-substituted alkyl, alkenyl, alkinyl, alkoxy, alkenyloxy or alkinyloxy having in each case up to 6 carbon atoms, and R3 represents in each case optionally substituted heterocyclyl having 5 ring members, at least one of which represents oxygen, sulphur or nitrogen and one to three others may represent nitrogen, and salts of compounds of the formula (I), to processes and novel intermediates for preparing the novel compounds and to their use as herbicides.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: May 7, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus-Helmut Müller, Ernst Rudolf F. Gesing, Mark Wilhelm Drewes, Johannes Rudolf Jansen, Rolf Kirsten, Joachim Kluth, Klaus König, Ulrich Philipp, Markus Dollinger
  • Patent number: 6323230
    Abstract: Derivatives of general chemical formula L(I) and (IV) are used in the topical treatment of diseases of the epithelial tissues, like psoriasis (epidermis) and ulcerative colitis L(lower intestine). These compounds display a high efficacy when administered for example by epicuaneous route in the case of dermatological illnesses like psoriasis, atopic dermatitis and other similar affections, or when administered by oral or rectal route in the case of diseases of the epithelia of the lower intestine like the ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 24, 2000
    Date of Patent: November 27, 2001
    Assignee: Geange Ltd.
    Inventor: Carla Rossi
  • Patent number: 6265584
    Abstract: Water-soluble prodrugs of triazole antifungal compounds having a secondary or tertiary hydroxy group are provided. More particularly, new water-soluble triazole antifungal compounds are provided having the general formula wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxyl group and n, R1 and R2 are as defined in the specification.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: July 24, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas W. Hudyma, Oak K. Kim, Xiaofan Zheng
  • Patent number: 6251831
    Abstract: The invention relates to novel sulphonylamino(thio)carbonyl compounds of the formula (I), in which A represents a single bond, oxygen, sulphur or the group N—R, in which R represents hydrogen, alkyl, alkenyl, alkinyl or cycloalkyl, Q represents oxygen or sulphur, R1 represents hydrogen or formyl or represents in each case optionally substituted alkyl, alkenyl, alkinyl, alkylcarbonyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, cycloalkylcarbonyl or cycloalkylsulphonyl, R2 represents cyano or halogen or represents in each case optionally substituted alkyl, alkenyl, alkinyl, alkoxy, alkenyloxy or alkinyloxy, and R3 represents in each case optionally substituted heterocyclyl having 5 ring members of which at least one is oxygen, sulphur or nitrogen and from one to three further ring members can be nitrogen, and salts of compounds of the formula (I), the previously known compounds 4,5-dimethoxy-2-(2,5-dimethoxy-phenylsulphonylaminocarbonyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, 4,5-di
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: June 26, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus-Helmut Müller, Rolf Kirsten, Ernst Rudolf F. Gesing, Joachim Kluth, Mark Wilhelm Drewes, Kurt Findeisen, Johannes Rudolf Jansen, Klaus König, Hans-Jochem Riebel, Otto Schallner, Markus Dollinger, Hans-Joachim Santel
  • Patent number: 6232317
    Abstract: Imino-substituted phenyl compounds of the formula I where the substituents have the following meanings: z is a group A or B  where  # denotes the bond with the phenyl ring and  Ra is halogen, alkyl or alkoxy; y is halogen, alkyl, haloalkyl or alkoxy; n is 0, 1 or 2, it being possible for the radicals Y to be different if n=2; R1 is halogen, haloalkyl or alkoxy; R2 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl or haloalkynyl; R3 is cyano, alkyl, haloalkyl, alkoxy, cycloalkoxy, alkoxyalkyl;  unsubstituted or substituted cycloalkyl, aryl, aryloxy or arylmethylene, heteroaryl, heterocyclyl,  C(R3a)═N—OR3b or C(R3a)═CR3cR3d, where R3a, R3b, R3c, R3d independently of one another are hydrogen, alkyl or unsubstituted or substituted phenyl, processes for their preparation, and their use.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: May 15, 2001
    Assignee: BASF Aktiengesellschaft
    Inventors: Wassilios Grammenos, Herbert Bayer, Hubert Sauter, Thomas Grote, Andreas Gypser, Bernd Müller, Arne Ptock, Franz Röhl, Norbert Götz, Eberhard Ammermann, Volker Harries, Gisela Lorenz, Siegfried Strathmann
  • Patent number: 6200934
    Abstract: The invention relates to novel substituted arylsulphonylamino(thio)carbonyl-triazolin(thi)ones of the formula (I) useful as herbicides.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: March 13, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus-Helmut Müller, Mark Wilhelm Drewes, Ernst Rudolf F. Gesing, Johannes Rudolf Jansen, Rolf Kirsten, Joachim Kluth, Klaus König, Hans-Jochem Riebel, Otto Schallner, Kurt Findeisen, Markus Dollinger
  • Patent number: RE39607
    Abstract: The invention relates to novel sulphonylamino(thio) carbonyl compounds of the formula (I), in which A represents a single bond, oxygen, sulphur or the group N—R, in which R represents hydrogen, alkyl, alkenyl, alkinyl or cycloalkyl, Q represents oxygen or sulphur, R1 represents hydrogen or formyl or represents in each case optionally substituted alkyl, alkenyl, alkinyl, alkylcarbonyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, cycloalkylcarbonyl or cycloalkylsulphonyl, R2 represents cyano or halogen or represents in each case optionally substituted alkyl, alkenyl, alkinyl, alkoxy, alkenyloxy or alkinyloxy, and R3 represents in each case optionally substituted heterocyclyl having 5 ring members of which at least one is oxygen, sulphur or nitrogen and from one to three further ring members can be nitrogen, and salts of compounds of the formula (I), the previously known compounds 4,5-dimethoxy-2-(2,5-dimethoxy-phenylsulphonylaminocarbonyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, 4,5-diethoxy-2-(2,5-dimetho
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: May 1, 2007
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus-Helmut Müller, Rolf Kirsten, Ernst Rudolf F. Gesing, Joachim Kluth, Mark Wilhelm Drewes, Kurt Findeisen, Johannes Rudolf Jansen, Klaus König, Hans-Jochem Riebel, Otto Schallner, Markus Dollinger, Hans-Joachim Santel